Lemaitre Vascular (LMAT) Cash & Equivalents (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of Cash & Equivalents data on file, last reported at $26.9 million in Q1 2026.

• Quarterly Cash & Equivalents rose 5.96% year-over-year to $26.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.9 million (up 5.96% YoY) and the FY2025 annual result came in at $28.2 million, up 10.29% from the prior year.
• Cash & Equivalents fell to $26.9 million in Q1 2026 per LMAT's latest filing, from $28.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $28.2 million in Q4 2025 and bottomed at $15.6 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $22.3 million (2024), against an average of $22.3 million.
• The widest annual swing landed in 2022, when Cash & Equivalents plunged 33.86%; it then surged 59.47% in 2024.
• Tracing LMAT's Cash & Equivalents over 5 years: stood at $19.1 million in 2022, then grew by 26.84% to $24.3 million in 2023, then advanced by 5.53% to $25.6 million in 2024, then rose by 10.29% to $28.2 million in 2025, then declined by 4.93% to $26.9 million in 2026.
• Per Business Quant, the three latest LMAT Cash & Equivalents figures stand at $26.9 million (Q1 2026), $28.2 million (Q4 2025), and $25.5 million (Q3 2025).

Peer Comparison